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Based on two primary motivating factors,
namely the successful functional grafting of
embryonic nervous tissue to brain in animal
models of neurological disorders, and the need
of new therapeutic alternatives for many
patients with severe Parkinson’s disease, a
Neurotransplantation Program was initiated in
Cuba in 1984.
From April to December 1987, after carrying
out rodent neurografting studies, we performed
adrenal medulla autotransplantation on three
parkinsonian patients. From January 1988 to
April 1990, thirty patients with advanced Par-
kinson’s disease suffering from severe motor
complications associated with L-Dopa therapy
underwent fetal ventral mesencephalic tissue
transplantation in the caudate nucleus, using an
open microsurgical procedure.
The series of patients had a median age of 45
years (range 36-55); the evolution time of the
disease was 9 years (4-18), and the duration of
pre-operative L-Dopa treatment ranged from 1
to 12 years (median 7 years).
The clinical evaluations, based on inter-
national rating systems, were performed before
the operation and after 15 days, 1, 3, 6, 12, 18,
24, 30, 36, 48 and 52 months.
Several solid fragments (2-8, mean=6) of
ventral mesencephalic tissue from fetuses aged
6-12 weeks were implanted on the head of the
caudate nucleus using an open microsurgical
transfrontal approach to the lateral ventricle.
The mean time between abortion and implan-
tation was 45 minutes.
The evolution of the neurological condition of
the thirty patients, assessed during a long period
of follow-up, can be summarized as follows:
Significant improvements in motor complica-
tions associated with L-Dopa therapy, in-
eluding reductions in both the daily "off’ time
from 56% before surgery to 2% 42 months af-
ter transplantation, and the number of daily
"off" periods from 5.1 before to 1.5 after
grafting.
Better response to L-Dopa therapy in the
post-surgical stage.
Reduction in the post-operative daily L-Dopa
requirements from 984 mg/24 h before to 399
mg/24 h 42 months after operation.
Progressive improvement of the neurological
performance demonstrated by UPDRS
scores. This improvement was statistically sig-
nificant from 3 to 36 months after surgery
(Fig. 1).
The "off’ quality improvement in the post-
operative stage ranged from 46.3% in the 3rd
month to 49.6% in the 42nd.
Progressive alleviation of the major symptoms
of Parkinson’s disease, most pronounced
contralaterally to the graft, that contributed
to the enhancement of the patient’s quality of
life.
The results of this study demonstrated that
transplantation of fetal mesencephalon in
caudate nucleus can significantly improve the
neurological condition of selected parkinsonian
patients with severe clinical fluctuations as
complications of L-Dopa therapy for a long
period after surgery.
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Clinical evolution from 30 to 40 days before to 36 months after transplantation.
Progressive clinical improvement statistically significant from 3 to 36 months after grafting ([P_<O.01)
(Wilcoxon matched pairs test).